Drug intelligence / Profile preview

M-M-R II + Varivax

Development stage
Unknown
Lead developer
Merck
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

M-M-R II + Varivax refers to the concomitant administration of two live attenuated virus vaccines—M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) and Varivax (Varicella Virus Vaccine Live). Both are administered as separate injections but may be given during the same visit. - **M-M-R II** contains live attenuated strains of measles (Edmonston strain), mumps (Jeryl Lynn strain), and rubella (Wistar RA 27/3 strain) viruses. It induces immunity by stimulating the production of neutralizing antibodies against these viruses[1][7]. - **Varivax** contains a live attenuated Oka/Merck varicella-zoster virus. It induces immunity by stimulating an immune response that protects against chickenpox[8]. Both vaccines are indicated for active immunization in individuals 12 months of age or older to prevent their respective diseases. The mechanism of action is immune system activation via exposure to weakened forms of each virus.

Brand names
M-M-R IIVARIVAX
Other names
Measles, Mumps, and Rubella Virus Vaccine Live + Varicella Virus Vaccine Live

Beyond the preview

Go deeper on M-M-R II + Varivax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on M-M-R II + Varivax.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call